Compounded peptides and medications
A compounded medication is prepared by a licensed pharmacy for an individual prescription rather than manufactured in a factory. It's how providers prescribe compounded peptides and other molecules that have no commercial version and adjust formulations to a patient — and it comes with its own rules: compounded medications are not FDA-approved, and quality depends on the pharmacy's standards.
These articles explain how compounding works, how it's regulated, and what that means for the treatments you're prescribed.
226 articles on this topic
-
Compounded Semaglutide Adverse Events: FDA Update
FDA now lists 990 adverse-event reports associated with compounded semaglutide and more than 730 with compounded tirzepatide. The counts matter, but they are reports rather than proof of cause or a rate of harm.
-
FLOW Trial Semaglutide Results: What 24% Means
FLOW followed 3,533 adults with type 2 diabetes and chronic kidney disease. The headline was a 24% lower risk for a bundle of serious kidney and cardiovascular outcomes, not a promise that kidney disease would disappear.
-
Semaglutide Myths: 10 Claims Checked
Ten common semaglutide claims, checked against clinical trials, current prescribing information, and FDA findings.
-
Tesamorelin Clinical Trials: What the Studies Show
The large trials found less visceral abdominal fat in adults with HIV-associated lipodystrophy. They did not test general weight loss, anti-aging, or the compounded formulations sold today.
-
Tirzepatide Injection Site Reaction: What to Know
A small red, itchy, sore patch or raised spot can be a tirzepatide injection site reaction. The Zepbound label reports these reactions in 6% to 8% of treated adults, but a spreading or whole-body reaction is a different concern.
-
20 Percent Weight Loss: What the Numbers Show
Twenty percent weight loss is 40 pounds from a 200-pound starting weight. In two large trials, that headline also came with changes in waist size, blood pressure and lab results—but it was an average, not a promise.
-
Who Discovered GHRH? The Two 1982 Teams
Two independent teams identified GHRH in 1982, using an unexpected clue from pancreatic tumors. Their papers opened the path to sermorelin, tesamorelin and CJC-1295.
-
Generic Tirzepatide: Under Review, Not Approved
FDA has accepted applications for proposed generic tirzepatide autoinjectors, but none can be sold in the United States yet. Review, approval and launch are three different milestones.
-
KPV FDA Review: What the July Vote Really Changed
KPV has never been approved as a U.S. drug. A July 2026 advisory vote favored possible 503A listing, but it did not change the list or approve a product.
-
MOTS-c Exercise Claims: What the Studies Show
MOTS-c is called an exercise mimetic because exercise raises it in people and administered MOTS-c changed running performance in mice. No published human trial shows that taking it improves a workout.
-
Who Discovered TB-500? The Full Story
The short answer starts with Teresa Low, Shu-Kuang Hu, and Allan Goldstein, who sequenced thymosin beta-4 in 1981. The seven-amino-acid fragment now called TB-500 came later, and the record does not name one inventor.
-
BPC-157 News Update: September 2026
A July FDA advisory vote moved the conversation forward, but it did not change the law or establish that BPC-157 works in people. A new rat study adds evidence, with the same important limit: it was not a human trial.
-
Hims Peptides: What Hims & Hers Plans to Sell
Hims & Hers says a peptide and wellness category is coming, but the rollout is phased. Some offerings are planned for 2026, while BPC-157 depends on unfinished FDA rulemaking.
-
What Is an IND? A Plain-English FDA Guide
An IND is the filing that lets a sponsor begin testing an investigational drug in people. It opens a research path, not a sales or prescription path.
-
5 Percent Weight Loss Benefits: Study Numbers
Five percent can be a meaningful first milestone. Here's what studies measured in blood sugar, blood pressure, and sleep, and where the numbers stop being a useful prediction.
-
BPC-157 and Alcohol: Can You Drink Safely?
No published human study has tested the combination. The alcohol claims come from experiments in mice and rats, which cannot establish a safe drinking amount or a hangover remedy.
-
SELECT Trial Semaglutide Results: What 20% Means
SELECT recorded fewer major heart and blood-vessel events with branded semaglutide. Here is what the 20% headline means, who was studied, and where the evidence stops.
-
Who Discovered Kisspeptin? The People Behind It
Danny Welch's cancer research started the story in 1996. Other teams found the peptide, connected it to puberty, and brought it into human studies.
-
FDA Category 2 Bulk Drug Substances: What It Means
Category 2 means FDA has identified significant safety concerns about a nominated compounding ingredient. Here is what the category tells a patient, and why leaving it does not mean approval.
-
Gray Market Peptides: What Johns Hopkins Found
Johns Hopkins says the market for unverified peptide vials is growing much faster than the human evidence. The useful question is what a prescription and a pharmacy change.
Page 1 of 12 · 226 articles